Related Experiment Videos
The Orphan Drug Act and the Federal Government's Orphan Products Development Program
Public Health Reports (Washington, D.C. : 1974)
|May 1, 1984
Summary
Public and private sector collaborations have successfully developed orphan drugs, addressing unmet medical needs. Continued cooperation is expected to sustain progress in rare disease therapeutics.
Area of Science:
- Pharmacology
- Public Health Policy
- Drug Development
Background:
- Orphan drug development faces significant challenges due to small patient populations.
- Limited commercial incentives historically hindered research into rare diseases.
- The orphan drug issue requires dedicated focus and resources.
Purpose of the Study:
- To highlight the success of collaborative efforts in orphan drug availability.
- To emphasize the importance of public-private partnerships in rare disease treatment.
- To project the future sustainability of these cooperative initiatives.
Main Methods:
- Analysis of successful orphan drug initiatives.
- Review of public and private sector contributions.
- Assessment of collaborative models in drug development.
Main Results:
- Numerous orphan drugs have become available through focused efforts.
- Public-private partnerships have been crucial for overcoming development hurdles.
- The initial momentum of orphan drug programs is expected to persist.
Conclusions:
- Combined public and private sector efforts are vital for orphan drug success.
- Sustained collaboration is anticipated to drive future advancements in rare disease therapies.
- The focus on the orphan drug issue has yielded significant therapeutic gains.